연구동향 분석

The Evolving Concept of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: Focus on Unique Feature of East Asian and “Asian Paradox”

강지훈 김효수 2018년

논문상세정보
    • 저자 강지훈 김효수
    • 제어번호 105479304
    • 학술지명 Korean Circulation Journal
    • 권호사항 Vol. 48 No. 7 [ 2018 ]
    • 발행처 대한심장학회
    • 발행처 URL http://www.circulation.or.kr
    • 자료유형 학술저널
    • 수록면 537-551
    • 언어 English
    • 출판년도 2018
    • 등재정보 KCI등재
    • 판매처
    유사주제 논문( 0)
인용/피인용

' The Evolving Concept of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: Focus on Unique Feature of East Asian and “Asian Paradox”' 의 참고문헌

  • Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents
    Mauri L [2014]
  • Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial
    James S [2010]
  • Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study
    Goto S [2015]
  • Ticagrelor versus clopidogrel in patients with acute coronary syndromes
    Wallentin L [2009]
  • Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis
    Steg PG [2010]
  • Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial
    James S [2010]
  • Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: a retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial
    Kang HJ [2015]
  • Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial
    Feres F [2013]
  • Third-generation P2Y12 inhibitors in east Asian acute myocardial infarction patients: a nationwide prospective multicentre study
    Kang J [2018]
  • The Use Pattern and Clinical Impact of New Antiplatelet Agents Including Prasugrel and Ticagrelor on 30-day Outcomes after Acute Myocardial Infarction in Korea: Korean Health Insurance Review and Assessment Data
    김충기 [2017]
  • Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial
    Helft G [2016]
  • Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention:the GRAVITAS randomized trial
    Price MJ [2011]
  • Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study
    Gwon HC [2012]
  • Six versus 12 months of dual antiplatelet therapy after implantation of biodegradable polymer sirolimus-eluting stent: randomized substudy of the I-LOVE-IT 2 trial
    Han Y [2016]
  • Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial
  • Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial
    Colombo A [2014]
  • Role of adipose tissue in haemostasis, coagulation and fibrinolysis
    Faber DR [2009]
  • Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study
  • Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation
    Shen AY [2007]
  • Prasugrel versus clopidogrel in patients with acute coronary syndromes
    Wiviott SD [2007]
  • Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial
  • Polymer-free drug-coated coronary stents in patients at high bleeding risk
    Urban P [2015]
  • Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial
    Roberts JD [2012]
  • Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial
    Cayla G [2016]
  • Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry
    Sahlen A [2016]
  • Options to overcome clopidogrel response variability
    Park KW [2012]
  • Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial
    Lee CW [2014]
  • Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial
    Suh JW [2011]
  • Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis
    Smith PK [2012]
  • Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data
    Brar SS [2011]
  • ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting
  • High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI
    Parodi G [2011]
  • Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI
    Levine GN [2014]
  • Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study
    Mak KH [2009]
  • Ethnic differences in ischemia/bleeding risk tradeoff during antiplatelet therapy after drug-eluting stent implantation: individual patient level meta-analysis from seven RCTs
    Kang J [2018]
  • Efficacy of cilostazol on inhibition of platelet aggregation, inflammation and myonecrosis in acute coronary syndrome patients undergoing percutaneous coronary intervention: The ACCEL-LOADING-ACS (ACCELerated inhibition of platelet aggregation, inflammation and myonecrosis by adjunctive cilostazol loading in patients with acute coronary syndrome) study
    Lee K [2015]
  • Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study
    Saito S [2014]
  • Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation
    Yusuf S [2001]
  • Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial
  • Duration of dual antiplatelet therapy: a systematic review for the 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines
    Bittl JA [2016]
  • Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial
    Collet JP [2014]
  • Dual antiplatelet therapy for 6 versus 18 months after biodegradable polymer drug-eluting stent implantation
    Nakamura M [2017]
  • Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS)
    Bertrand ME [2000]
  • Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects
    Hulot JS [2006]
  • Continuation of dual-antiplatelet therapy following percutaneous revascularization with a drug-eluting stent: what duration is optimal?
    Patil RK [2015]
  • Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate
    Bonello L [2010]
  • Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events
    Bhatt DL [2006]
  • Clinical predictors of high posttreatment platelet reactivity to clopidogrel in Koreans
    Park KW [2012]
  • Clinical outcomes of high on-treatment platelet reactivity in Koreans receiving elective percutaneous coronary intervention (from results of the CROSS VERIFY study)
    Park KW [2011]
  • CYP2C19 phenotype, stent thrombosis, myocardial infarction, and mortality in patients with coronary stent placement in a Chinese population
    Xie X [2013]
  • Bedside monitoring to adjust antiplatelet therapy for coronary stenting
    Collet JP [2012]
  • Association of different antiplatelet therapies with mortality after primary percutaneous coronary intervention
    Olier I [2018]
  • Amlodipine, clopidogrel and CYP3A5 genetic variability: effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention
    Park KW [2012]
  • Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing optimal strategy for treatment of coronary artery stenosis-safety & effectiveness of drug-eluting stents & anti-platelet regimen)
    Park KW [2013]
  • Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial
    Chen ZM [2005]
  • Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation
    Sabatine MS [2005]
  • A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents
    Schomig A [1996]
  • A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation)
    Kim BK [2012]
  • 6-month versus 12-month dual-antiplatelet therapy following long everolimus-eluting stent implantation: The IVUS-XPL randomized clinical trial
    Hong SJ [2016]
  • 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial
    Gilard M [2015]
  • 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS : The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology(ESC)and of the European Association for Cardio-Thoracic Surgery(EACTS)
  • 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
  • 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery
    Levine GN [2016]
  • "East asian paradox": challenge for the current antiplatelet strategy of "one-guideline-fits-all races" in acute coronary syndrome
    Jeong YH [2014]